SPARFLOXACIN - POTENTIAL CLINICAL AND ECONOMIC-IMPACT IN THE TREATMENT OF RESPIRATORY-INFECTIONS

Sparfloxacin is a new oral fluoroquinolone antimicrobial that is highl y active against common respiratory pathogens, including multiresistan t strains. It is well absorbed and has excellent penetration into uppe r and lower respiratory tissues. Sparfloxacin is administered once a d ay and does not interfere with the metabolism of other drugs. The agen t is highly effective and safe in the treatment of acute sinusitis, ex acerbations of chronic bronchitis, and community-acquired pneumonia. D ue to its activity against multidrug-resistant respiratory pathogens, it has the potential to prevent hospitalization as well as decrease pa renteral antibiotic therapy. Consequently, it may generate significant pharmacoeconomic benefits to patients and payers of medical care.